Evidence map›Paper›PMID 39174837›Full record

ArticleAnnals of surgical oncology2024

Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma.

Helana Ghali, Michelle M Dugan, Shaliz Aflatooni, Aleena Boby, Danielle K DePalo, José Laborde, Junsung Choi, Altan F Ahmed, Jonathan S Zager

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Helana Ghali *University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Michelle M Dugan *Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Shaliz AflatooniUniversity of South Florida Morsani College of Medicine, Tampa, FL, USA.
Aleena BobyUniversity of South Florida Morsani College of Medicine, Tampa, FL, USA.
Danielle K DePaloDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
José LabordeDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Junsung ChoiDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA.
Altan F AhmedDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. jonathan.zager@moffitt.org.ORCID http://orcid.org/0000-0002-6886-4468

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUveal melanoma often metastasizes to the liver, portending a poor prognosis. Melphalan/hepatic delivery system (HDS) via percutaneous hepatic perfusion (PHP) is a minimally invasive means of circulating high-dose chemotherapy through the affected liver. This study evaluated melphalan/HDS use as either first-line or second-line treatment to guide treatment sequencing. PATIENTS AND

methodsA retrospective review included patients with hepatic-dominant metastatic uveal melanoma who underwent melphalan/HDS treatment via PHP from 2008 to 2023.

resultsA total of 30 patients were identified; 53.3% female, with a median age of 63.5 years (37-78 years). Median follow-up time was 14.5 months. First-line therapies included melphalan/HDS (n = 17), liver-directed (n = 7), and immunotherapy (n = 6). Second-line therapies included melphalan/HDS (n = 6), immunotherapy (n = 5), and liver-directed (n = 3). Median hepatic progression-free survival (hPFS) for first-line melphalan/HDS, immunotherapy, and liver-directed therapy was 17.6/8.8/9.2 months, respectively (P = 0.002). Median hPFS for second-line melphalan/HDS, immunotherapy, and liver-directed therapy was not reached/14.7/7.5 months, respectively (P < 0.001). Median overall PFS for first-line melphalan/HDS, immunotherapy, and liver-directed therapy was 15.4/8.8/9.2 months, respectively (P = 0.04). Median overall PFS for second-line melphalan/HDS, immunotherapy, and liver-directed therapy was 22.2/14.7/7.5 months, respectively (P = 0.001).

conclusionsMelphalan/HDS via PHP for metastatic uveal melanoma to the liver was found to have significantly improved hPFS and overall PFS when used as first-line therapy compared with immunotherapy or liver-directed therapy. PHP continued to demonstrate improved hPFS and PFS when used as second-line therapy compared with second-line immunotherapy or liver-directed therapy.

Indexed as

Antineoplastic Agents, AlkylatingChemotherapy, Cancer, Regional PerfusionLiver NeoplasmsMelanomaMelphalanUveal NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesAntineoplastic Agents, AlkylatingMelphalanHepatic delivery systemHepatic melanomaHepatic metastasesMelphalanMetastatic melanomaPercutaneous hepatic perfusionRegional chemotherapyTreatment line of therapyUveal melanoma

Identifiers

PMID39174837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.